CD40LG and infection: Patients treated with leniolisib experienced reductions in IgM levels versus patients treated with placebo in a 12-week phase III randomised controlled trial, and over a longer follow-up period in the OLE patients experienced a reduced number of infections, while 37% of patients who were receiving IRT at study entry reduced or discontinued IRT [31, 32].